Article DOI: https://doi.org/10.3201/eid2905.221646

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

US National Institutes of Health Prioritization of SARS-CoV-2 Variants

Appendix 2

| November 2022 | December 2022 | January 2023 | February 2023 |
|---|---|--|--|
| B 1.351 (Beta) B 1.617.1 (Kappa) B 1.1.7 + E484K B 1.1.7 (Alpha) B 1.427/429 (Epsilon) R.1 B 1.526 + E484K P 2 (Zeta) B 1.526 + L452R A 23.1 C.37 (Lambda) B 1.621 (Mu) B 1.617.2 + E484Q B 1.617.2 + V70F + A222V + K41 B 1.617.2 + V70F + A222V + K41 B 1.617.2 + T95I + W258L + K41 B A.1 BA.2 BA.2 / M0 | B.1.351 (Beta) B.1.617.1 (Kappa) B.1.1.7 (Alpha) B.1.47/429 (Epsilon) R.1 B.1.427/429 (Epsilon) R.1 B.1.526 + E484K B.1.526 + L452R A.23.1 C.37 (Lambda) B.1.621 (Mu) B.1.617.2 + YOF + A222V + K41 B.1.617.2 + T95I + W258L + K41 BA.2 BA.2 T5 | A 23.1 C 37 (Lambda) B.1.621 (Mu) B.1.617.2 + E484Q B.1.617.2 + V70F + A222V + K41 B.1.617.2 + T95I + W258L + K41 BA.1 BA.2 BA.2 BA.2 | B.1.351 (Beta) B.1.351 (Beta) B.1.617.1 (Kappa) B.1.1.7 + E484K B.1.1.7 + E484K B.1.1.7 (Alpha) B.1.427(429 (Epsilon)) R.1 B.1.526 + E484K P.2 (Zeta) B.1.526 + L452R C.37 (Lambda) B.1.617.2 + K484Q B.1.617.2 + K70F + A222V + K41 B.1.617.2 + T95I + W258L + K41 B.4.172 B.4.1817.2 + T95I + W258L + K41 |
| BA.4 / BA.5 BA.5 + R346T BA 1 + R346K (BA 1 1) | BA.4 / BA.5 BA.5 + R346T BA.5 + R346K BA.1 + R346K (BA.1.1) | BA.2 + L452U + 5704L | BA.4 / BA.5 BA.5 + R346T BA.1 + R346K (BA.1.1) BA.4 + R346K + N658S Ongoing BA.2.75 + R346T + F486S + D119 |
| Prioritisation XBB + G252V (XBB.1) XBB (BJ1/BM.11.1: recombinant BA.2.75 + R346T + F486S + D119 BA.5 + R346T + K444T + M460K (BA.2.320/CM 2 (BA.2 + 9 subs BA.2.75 + R346T + K356T + F490 BJ.1 (BA.2 + 13 subs.1 del) BA.5 + K444T + N460K (BQ.1) BQ.1 + Y144- BS.1 (BA.2 + 7 subs.1, del, 1 BA.5 + K444T BA.5 + K444T BA.5 + K444R BA.5 + K444R BA.5 + K444M Absent | Prioritisation BA.5 + R346T + K444T + N460K (BQ.11 + Y144- BA.5 + K444T + N460K (BQ.1) XBB + G252V (XBB.1) XBB (GL1/BM.1.1 recombinant BQ.1 + Y144- BA.275 + R346T + K356T + F490 BA.275 + R346T + L452R + F486 BA.275 + R346T + L452R + F486 BA.23.20/CM.2 (BA.2 + 9 subs) XBB + G252V + S486P XBC + L452M (XBC.1) BN.1 + E147Q CMA.1 (BA.2 3.20 + G446S + F44 BA.5 + K150E + K444N + N460K (BA.5 + K150E + K444N + N460K (BA.2 + 13 subs, 1 del) BA.2 + 75 + R346T + F486S + D119 BA.1 (BA.2 + 13 subs, 1, del, 1 XBB + G252V + S486P Absent | BA 2.75 + R346T + F486S + D119 Prioritisation XBB + G252V + S486P XBB + G252V + S486P XBB + G252V (XBB.1) BA 5 + R346T + K444T + N460K (XBB + D253G (XBB 2) BA 2.75 + R346T + K444T + L452 XBB (BJ.17BM.1.1 recombinant BA 2.75 + R346T + K456T + F490 BA 5 + K444T + N460K (BQ.1) BA 2.75 + R346T + K356T + F490 BA 5 + K444T + N460K (BQ.1) BA 2.75 + R346T + K356T + F490 BA 2.75 + R346T + K452R + F486 BQ 1 + Y144- BA 2.3 20/CM 2 (BA 2 + 9 subs, Absent | BA2.75 + R346T + F4486 + D119 BA5 + R346T + K444T + N460K (XBB (BJ.1/BM.1.1.1 recombinant Prioritisation BA5 + R346T + K444T + L452 XBF / BA2.75 + R346T + K444T + L452 XBF / BA2.75 + R346T + K444T + L452 XBF / BA2.75 + R346T + K444T + L452 XBF / BA2.75 + R346T + K446T + L452 KB + G252V (XBE.1) BQ.1 + Y144 - BA2.75 + R346T + K356T + F490 BA.1 + E1470 BA.1 + E1470 BA.2 + K444T + N460K (BQ.1) BA.5 + A570S (BA.5.2.48) BA.2 / AY.42 chimera (XAY.2) Absent |

Appendix 2 Figure. US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 assessment of Viral Evolution Early Detection consortium prioritization of variant rankings for November 2022–February 2023. The prioritizations are produced by taking the consensus of rankings provided by consortium subgroups. Lineages are colored by their prioritization category in the February 2023 ranking (including "well studied" and "ongoing" categories). Equivalent figures colored for each other

month are available in Appendix 3 (<u>https://wwwnc.cdc.gov/EID/article/29/5/22-1646-App3.pdf</u>). Colored bars indicate priority categories 1, 2, and 3 in each month. These prioritizations, and all future prioritizations, can be accessed with supporting information online as outlined in in the main text or in Appendix 1 (<u>https://wwwnc.cdc.gov/EID/article/29/5/22-1646-App1.pdf</u>).